Review



discovery studio client software version 2016  (Accelrys)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Accelrys discovery studio client software version 2016
    CYP51 contributed to the conversion of FLZ to M1 in the gut microbiota. Molecular docking was performed by BIOVIA <t>Discovery</t> <t>Studio</t> <t>Client</t> <t>software</t> to study the binding activity of CYP51 to FLZ. (A) Molecular docking 3D diagram of FLZ and CYP51. (B) Molecular docking 2D diagram of FLZ and CYP51. The colonic contents were extracted from mice and then incubated with FLZ and Itraconazole or Voriconazole for 6 h. (C) The activity of CYP51 in gut microbiota. (D) The ratio of M1/FLZ in gut microbiota. Data are presented as mean ± SD ( n = 4 in each group). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.
    Discovery Studio Client Software Version 2016, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/discovery+studio+client+software+version+2016/pmc08148066-81-1-7?v=Accelrys
    Average 90 stars, based on 1 article reviews
    discovery studio client software version 2016 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment"

    Article Title: Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment

    Journal: Acta Pharmaceutica Sinica. B

    doi: 10.1016/j.apsb.2021.01.009

    CYP51 contributed to the conversion of FLZ to M1 in the gut microbiota. Molecular docking was performed by BIOVIA Discovery Studio Client software to study the binding activity of CYP51 to FLZ. (A) Molecular docking 3D diagram of FLZ and CYP51. (B) Molecular docking 2D diagram of FLZ and CYP51. The colonic contents were extracted from mice and then incubated with FLZ and Itraconazole or Voriconazole for 6 h. (C) The activity of CYP51 in gut microbiota. (D) The ratio of M1/FLZ in gut microbiota. Data are presented as mean ± SD ( n = 4 in each group). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.
    Figure Legend Snippet: CYP51 contributed to the conversion of FLZ to M1 in the gut microbiota. Molecular docking was performed by BIOVIA Discovery Studio Client software to study the binding activity of CYP51 to FLZ. (A) Molecular docking 3D diagram of FLZ and CYP51. (B) Molecular docking 2D diagram of FLZ and CYP51. The colonic contents were extracted from mice and then incubated with FLZ and Itraconazole or Voriconazole for 6 h. (C) The activity of CYP51 in gut microbiota. (D) The ratio of M1/FLZ in gut microbiota. Data are presented as mean ± SD ( n = 4 in each group). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.

    Techniques Used: Software, Binding Assay, Activity Assay, Incubation, Control

    COMT contributed to the conversion of M1 to FLZ in the blood. Blood was collected from mice and then incubated with FLZ or M1 for 120 min. (A) Incubation of FLZ with mouse blood. (B) Incubation of M1 with mouse blood. BIOVIA Discovery Studio Client software was used to perform molecular docking of M1 and COMT. (C) Molecular docking 3D diagram. (D) Molecular docking 2D diagram. Mice blood were extracted from mice and then incubated with M1 and entacapone for 120 min: (E) The activity of COMT in the blood. (F) The ratio of FLZ/M1 in the blood. Data are presented as mean ± SD ( n = 4 in each group). ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.
    Figure Legend Snippet: COMT contributed to the conversion of M1 to FLZ in the blood. Blood was collected from mice and then incubated with FLZ or M1 for 120 min. (A) Incubation of FLZ with mouse blood. (B) Incubation of M1 with mouse blood. BIOVIA Discovery Studio Client software was used to perform molecular docking of M1 and COMT. (C) Molecular docking 3D diagram. (D) Molecular docking 2D diagram. Mice blood were extracted from mice and then incubated with M1 and entacapone for 120 min: (E) The activity of COMT in the blood. (F) The ratio of FLZ/M1 in the blood. Data are presented as mean ± SD ( n = 4 in each group). ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.

    Techniques Used: Incubation, Software, Activity Assay, Control



    Similar Products

    discovery studio client software version 2016  (Accelrys)
    90
    Accelrys discovery studio client software version 2016
    CYP51 contributed to the conversion of FLZ to M1 in the gut microbiota. Molecular docking was performed by BIOVIA <t>Discovery</t> <t>Studio</t> <t>Client</t> <t>software</t> to study the binding activity of CYP51 to FLZ. (A) Molecular docking 3D diagram of FLZ and CYP51. (B) Molecular docking 2D diagram of FLZ and CYP51. The colonic contents were extracted from mice and then incubated with FLZ and Itraconazole or Voriconazole for 6 h. (C) The activity of CYP51 in gut microbiota. (D) The ratio of M1/FLZ in gut microbiota. Data are presented as mean ± SD ( n = 4 in each group). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.
    Discovery Studio Client Software Version 2016, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/discovery+studio+client+software+version+2016/pmc08148066-81-1-7?v=Accelrys
    Average 90 stars, based on 1 article reviews
    discovery studio client software version 2016 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    CYP51 contributed to the conversion of FLZ to M1 in the gut microbiota. Molecular docking was performed by BIOVIA Discovery Studio Client software to study the binding activity of CYP51 to FLZ. (A) Molecular docking 3D diagram of FLZ and CYP51. (B) Molecular docking 2D diagram of FLZ and CYP51. The colonic contents were extracted from mice and then incubated with FLZ and Itraconazole or Voriconazole for 6 h. (C) The activity of CYP51 in gut microbiota. (D) The ratio of M1/FLZ in gut microbiota. Data are presented as mean ± SD ( n = 4 in each group). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment

    doi: 10.1016/j.apsb.2021.01.009

    Figure Lengend Snippet: CYP51 contributed to the conversion of FLZ to M1 in the gut microbiota. Molecular docking was performed by BIOVIA Discovery Studio Client software to study the binding activity of CYP51 to FLZ. (A) Molecular docking 3D diagram of FLZ and CYP51. (B) Molecular docking 2D diagram of FLZ and CYP51. The colonic contents were extracted from mice and then incubated with FLZ and Itraconazole or Voriconazole for 6 h. (C) The activity of CYP51 in gut microbiota. (D) The ratio of M1/FLZ in gut microbiota. Data are presented as mean ± SD ( n = 4 in each group). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.

    Article Snippet: BIOVIA Discovery Studio Client software (version 2016; Accelrys, Inc., San Diego, CA, USA) was employed to perform the molecular docking of FLZ onto the lanosterol 14-alpha-demethylase (CYP51, https://doi.org/10.2210/pdb5ESE/pdb ), and M1 onto the catechol O -methyltransferase (COMT, https://doi.org/10.2210/pdb4O0Q/pdb ).

    Techniques: Software, Binding Assay, Activity Assay, Incubation, Control

    COMT contributed to the conversion of M1 to FLZ in the blood. Blood was collected from mice and then incubated with FLZ or M1 for 120 min. (A) Incubation of FLZ with mouse blood. (B) Incubation of M1 with mouse blood. BIOVIA Discovery Studio Client software was used to perform molecular docking of M1 and COMT. (C) Molecular docking 3D diagram. (D) Molecular docking 2D diagram. Mice blood were extracted from mice and then incubated with M1 and entacapone for 120 min: (E) The activity of COMT in the blood. (F) The ratio of FLZ/M1 in the blood. Data are presented as mean ± SD ( n = 4 in each group). ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment

    doi: 10.1016/j.apsb.2021.01.009

    Figure Lengend Snippet: COMT contributed to the conversion of M1 to FLZ in the blood. Blood was collected from mice and then incubated with FLZ or M1 for 120 min. (A) Incubation of FLZ with mouse blood. (B) Incubation of M1 with mouse blood. BIOVIA Discovery Studio Client software was used to perform molecular docking of M1 and COMT. (C) Molecular docking 3D diagram. (D) Molecular docking 2D diagram. Mice blood were extracted from mice and then incubated with M1 and entacapone for 120 min: (E) The activity of COMT in the blood. (F) The ratio of FLZ/M1 in the blood. Data are presented as mean ± SD ( n = 4 in each group). ∗∗ P < 0.01, ∗∗∗ P < 0.001 vs. Control.

    Article Snippet: BIOVIA Discovery Studio Client software (version 2016; Accelrys, Inc., San Diego, CA, USA) was employed to perform the molecular docking of FLZ onto the lanosterol 14-alpha-demethylase (CYP51, https://doi.org/10.2210/pdb5ESE/pdb ), and M1 onto the catechol O -methyltransferase (COMT, https://doi.org/10.2210/pdb4O0Q/pdb ).

    Techniques: Incubation, Software, Activity Assay, Control